Latest oncology resources and news surrounding Novartis data featured at European Society for Medical Oncology (ESMO)
Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.
AI offers the greatest potential to transform health systems from being reactive to proactive, predictive, and even preventive.
Blood diseases place a huge burden on individual patients, their families and on wider society. Yet advances in hematology treatment give so much cause for hope. It’s our responsibility to turn that hope into reality. Hear from five bold advocates who inspire us.
At Novartis, we aim to be a leader in environmental sustainability and a catalyst for positive change both in our own operations and in our supply chain.
Novartis has appointed Marc Boutin as Global Head of Patient Engagement & Advocacy. He will join Novartis no later than November 1, 2020.
Novartis now offers many associates the choice to decide how, where and when they work* to create the greatest impact for their role while taking personal responsibility to inform managers and align with teammates for effective collaboration, based on the nature of their work.
European Medicines Agency (EMA) recently approved two European Novartis sites for commercial CAR-T manufacturing.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.
This site is intended for a global audience.